Evidence map›Paper›PMID 36612120›Full record

ArticleCancers2022

Tumor Cell-Derived Exosomal circ-PRKCI Promotes Proliferation of Renal Cell Carcinoma via Regulating miR-545-3p/CCND1 Axis.

Yiguan Qian, Yang Li, Luwei Xu, Ke Chen, Ning Liu, Xiaobing Yang, Qian Lv, Rongfei Li, Changcheng Zhou, Zheng Xu and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Wogonin inhibits hepatoma cell proliferation by targeting miR-27b-5p/YWHAZ axis.Journal of biochemical and molecular toxicology · 2023
    Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Yiguan QianDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.ORCID 0000-0002-6715-4536
Yang LiDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Luwei XuDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Ke ChenDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Ning LiuDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Xiaobing YangDepartment of Pathology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Qian LvDepartment of Pathology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Rongfei LiDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Changcheng ZhouDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Zheng XuDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Ruipeng JiaDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Yu-Zheng GeDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.ORCID 0000-0003-1615-9473
Nanjing Medical University · CN

Funding

Nanjing Medical Science and Technology Development Foundation for Distinguished Young Scholars JQX18003National Natural Science Foundation of China 81802531National Natural Science Foundation of China 92049111Natural Science Foundation of Jiangsu Province BK20170135Science and Technology Foundation of Nanjing Medical University NMUB2019146"Six Talent Summit" Foundation of Jiangsu Province 2019-WSW-108Youth Medical Talent Program of Jiangsu Province QNRC2016073
6 · The paper itself

Abstract

Renal cell carcinoma (RCC) originates from the epithelial cells of the renal tubules and has a high degree of malignancy and heterogeneity. Recent studies have found that exosomes regulate intercellular communication via transferring various bioactive molecules, such as circular RNAs (circRNAs), which are critical for cancer progression. However, the role of tumor cell-derived exosomal circRNAs in RCC remains unclear. In this study, we reported the high expression of circ-PRKCI in RCC tissues and serum exosomes. We also found that circ-PRKCI could be transferred exosomally from highly malignant RCC cells to relatively less malignant RCC cells. Tumor cell-derived exosomal circ-PRKCI promoted the proliferation, migration, and invasion of RCC cells, while inhibiting their apoptosis. Mechanistically, we found that circ-PRKCI promoted the proliferation of RCC via the miR-545-3p/CCND1 signaling pathway. Our study is the first to report the potential mechanisms of tumor cell-derived exosomal circ-PRKCI in RCC. In conclusion, this study will provide a new understanding about the molecular mechanisms of RCC progression.

Indexed as

circ-PRKCIcyclin D1exosomemicroRNA-545-3pproliferationrenal cell carcinoma

Identifiers

PMID36612120
PMCPMC9817713
OpenAlexW4313260980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.